Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches

Martin F. Kaiser, Matthew Jenner, MBBS, MRCP, FRCPath, David Cairns, MSc, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Andrea Paterson, Rebecca Mottram, BA, BSc, Faith E. Davies, MD, Mark T Drayson, MB ChB, PhD FRCPath, Roger G. Owen, MD, Gareth Morgan, MDPhDFRCP, Gordon Cook, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD

Blood (2019) 134 (Supplement_1): 604.

https://doi.org/10.1182/blood-2019-124819

Published: 2019

Journal Articles

Risk Stratification and Transfusion Dependence Are Independent Risk Factors for Cardiovascular Disease (CVD) in Myelodysplastic Syndrome (MDS)

Diego Adrianzen Herrera, MD, Kith Pradhan, PhD, Rosebella Snyder, MD, Siddharth Karanth, MBBS, MPH, DrPH, Murali Janakiram, MD MS, Ioannis Mantzaris, MD MS, Santosh Murthy, MD MPH, Amit Verma, MBBS, Aditi Shastri, MD

Blood (2019) 134 (Supplement_1): 336.

https://doi.org/10.1182/blood-2019-123317

Published: 2019

Journal Articles

Risk Factors and Trends for Incidence of Acute Coronary Syndrome after Hematopoietic Stem Cell Transplant - a 15-Year Experience with National Inpatient Sample

Jasdeep Singh Sidhu, MBBS, Jeevanjot Kaur Virk, MBBS, Shivani Handa, MBBS, Amrendra Mandal, Sridevi Rajeeve, MD

Blood (2019) 134 (Supplement_1): 4564.

https://doi.org/10.1182/blood-2019-127487

Published: 2019

Journal Articles

Significance of Modified Risk Stratification Msmart 3.0 and Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma

Andrey Garifullin, MD, Sergei Voloshin, MD PhD, Vasily Shuvaev, MD, Irina Martynkevich, MD PhD, Elizaveta Kleina, Alexander Chechetkin, Stanislav Bessmeltcev, Anastasiya Kuzyaeva, Alexander Sсhmidt, Alexey Kuvshinov, MD, Irina Pavlova

Blood (2019) 134 (Supplement_1): 5593.

https://doi.org/10.1182/blood-2019-130092

Published: 2019

Journal Articles

Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss

Xiaochuan Yang, Amber C. King, PharmD, BCOP, Charlene C. Kabel, PharmD, Christopher J. Forlenza, MD, Jae H. Park, MD, Mark B. Geyer, MD

Blood (2019) 134 (Supplement_1): 3888.

https://doi.org/10.1182/blood-2019-125165

Published: 2019

Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Blood (2019) 134 (Supplement_1): 3806.

https://doi.org/10.1182/blood-2019-129018

Published: 2019

Journal Articles

A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia

Nitin Jain, MD, Kristen E. Stevenson, MS, Eric S. Winer, MD, Jacqueline S Garcia, MD, Richard M. Stone, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Jeremy M. Stewart, BA, Dean R Legg, BA, Hagop M. Kantarjian, MD, Donna S Neuberg, ScD, Anthony G. Letai, MD PhD, Marina Y Konopleva, MD PhD, Daniel J. DeAngelo, MD

Blood (2019) 134 (Supplement_1): 3867.

https://doi.org/10.1182/blood-2019-129988

Published: 2019

Journal Articles

Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A ( MLL ) Rearrangement

Blood (2019) 134 (Supplement_1): 2582.

https://doi.org/10.1182/blood-2019-130864

Published: 2019

Journal Articles

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Blood (2019) 134 (Supplement_1): 823.

https://doi.org/10.1182/blood-2019-125136

Published: 2019

Journal Articles

Monitoring Sickle Cell Disease Using Spectral-Domain Optic Coherence Tomography in Pediatric Patients

Jing Jin, MD PhD, Robin E Miller, MD

Blood (2019) 134 (Supplement_1): 994.

https://doi.org/10.1182/blood-2019-123138

Published: 2019

Journal Articles

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

Ruth M de Tute, PhD FRCPath, David Cairns, BSc, MSc, PhD, Andy Rawstron, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, John R Jones, MD, Martin F Kaiser, MD, Anna Hockaday, Alina Striha, MSc, Rowena Henderson, PhD, Gordon Cook, PhD, Nigel H. Russell, Mark T Drayson, MD PhD, Matthew W Jenner, Walter M Gregory, PhD, Graham Jackson, MDPhD, Gareth J. Morgan, MD PhD, Roger G. Owen, MD

Blood (2017) 130 (Supplement 1): 904.

https://doi.org/10.1182/blood.V130.Suppl_1.904.904

Published: 2017

Journal Articles

Genetic polymorphisms of vein wall remodeling in chronic venous disease: a narrative and systematic review

Vighnesh Bharath, Susan R. Kahn, Alejandro Lazo-Langner

Blood (2014) 124 (8): 1242–1250.

https://doi.org/10.1182/blood-2014-03-558478

Published: 2014

Journal Articles

A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.

Christopher P Venner, MD, Thirusha Lane, RN, Darren Foard, RN, Lisa Rannigan, RN, Shameem Mahmood, MBBCh. FRCPath, Simon DJ Gibbs, Jennifer Pinney, MD, Sanjay Banypersad, MD, Jason Dungu, Carol Whelan, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD

Blood (2012) 120 (21): 2966.

https://doi.org/10.1182/blood.V120.21.2966.2966

Published: 2012

Journal Articles

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

Christopher P. Venner, Thirusha Lane, Darren Foard, Lisa Rannigan, Simon D. J. Gibbs, Jennifer H. Pinney, Carol J. Whelan, Helen J. Lachmann, Julian D. Gillmore, Philip N. Hawkins, Ashutosh D. Wechalekar

Blood (2012) 119 (19): 4387–4390.

https://doi.org/10.1182/blood-2011-10-388462

Published: 2012

Journal Articles

Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,

Christopher P. Venner, MD, Julian D Gillmore, Thirusha Lane, RN, Darren Foard, RN, Lisa Rannigan, RN, Simon DJ Gibbs, Jennifer Pinney, MD, Carol Whelan, Helen Lachmann, MD, Philip N Hawkins, Ashutosh Wechalekar, MD

Blood (2011) 118 (21): 3975.

https://doi.org/10.1182/blood.V118.21.3975.3975

Published: 2011

Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,

Blood (2011) 118 (21): 3978.

https://doi.org/10.1182/blood.V118.21.3978.3978

Published: 2011

Journal Articles

Bone Marrow Transplantation Arrests Cerebrovascular Disease Progression and Improves Psychometric Outcomes in Children with Sickle Cell Disease

Neha Bhatnagar, MBChB, MRCPCH, Ruth Erskine, Farah O'Boyle, Subarna Chakravorty, PhD, FRCPath, MRCPCH, Irene Roberts, MD, Josu de la Fuente, PhD, FRCP, FRCPath

Blood (2011) 118 (21): 11.

https://doi.org/10.1182/blood.V118.21.11.11

Published: 2011

Journal Articles

Comparison of the Villalta Post Thrombotic Syndrome (PTS) Score in the Ipsilateral Versus Contralateral Leg After a First Unprovoked Deep Vein Thrombosis (DVT): Results From the REVERSE Study

Jean-Philippe Galanaud, Susan R. Kahn, MD, MSc, Michael Kovacs, Christina Holcroft, Marisol Betancourt, Philip S Wells, David Anderson, Isabelle Chagnon, MD, Gregoire Le Gal, MD, PhD, Susan Solymoss, MD, Mark A. Crowther, MD, FRCPC, Arnaud Perrier, Richard H. White, MD, Linda M Vickars, MD, FRCP(C), Tim Ramsay, Marc Rodger, MD, FRCPC

Blood (2011) 118 (21): 1236.

https://doi.org/10.1182/blood.V118.21.1236.1236

Published: 2011

Journal Articles

Dasatinib As a Late Second Line Therapy in Chronic Myeloid Leukemia Patients: A Retrospective Study From a Tertiary Care Centre in India

Tulika Seth, MD, Vandana Sharma, MSc, Sanjeev Sharma, Manoranjan Mahapatra, Pravas Mishra, Rajat Kumar, FRCP, Hara prasad Pati

Blood (2011) 118 (21): 4438.

https://doi.org/10.1182/blood.V118.21.4438.4438

Published: 2011

Journal Articles

Bortezomib Based Therapy for Newly Diagnosed Patients with Advanced Multisystem Light Chain Amyloidosis (AL)

Leena Varkey Maramattom, MD, Mazie Froedtert Willms & Sue Froedtert Cancer Fellow, Veerpal Singh, MD, Robert Frank Cornell, MD, Jasleen K Randhawa, MD, Mathew Thomas, Ayman A Saad, MD, Jeanne Palmer, MD, Parameswaran Hari, MBBS, MD, MRCP

Blood (2011) 118 (21): 1880.

https://doi.org/10.1182/blood.V118.21.1880.1880

Published: 2011

NARROW

Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches

Risk Stratification and Transfusion Dependence Are Independent Risk Factors for Cardiovascular Disease (CVD) in Myelodysplastic Syndrome (MDS)

Risk Factors and Trends for Incidence of Acute Coronary Syndrome after Hematopoietic Stem Cell Transplant - a 15-Year Experience with National Inpatient Sample

Significance of Modified Risk Stratification Msmart 3.0 and Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma

Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia

Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A ( MLL ) Rearrangement

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Monitoring Sickle Cell Disease Using Spectral-Domain Optic Coherence Tomography in Pediatric Patients

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

Genetic polymorphisms of vein wall remodeling in chronic venous disease: a narrative and systematic review

A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,

Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,

Bone Marrow Transplantation Arrests Cerebrovascular Disease Progression and Improves Psychometric Outcomes in Children with Sickle Cell Disease

Comparison of the Villalta Post Thrombotic Syndrome (PTS) Score in the Ipsilateral Versus Contralateral Leg After a First Unprovoked Deep Vein Thrombosis (DVT): Results From the REVERSE Study

Dasatinib As a Late Second Line Therapy in Chronic Myeloid Leukemia Patients: A Retrospective Study From a Tertiary Care Centre in India

Bortezomib Based Therapy for Newly Diagnosed Patients with Advanced Multisystem Light Chain Amyloidosis (AL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only